公开(公告)号：US20200345689A1

公开(公告)日：2020-11-05

申请号：US16960443

申请日：2019-01-08

申请人： EpicentRx, Inc.

发明人： Bryan T. ORONSKY ,  Amold ORONSKY

IPC分类号： A61K31/397 ,  A61K9/00 ,  A61K31/616 ,  A61K45/06 ,  A61K31/196 ,  A61K31/517 ,  A61K33/00 ,  A61N5/10 ,  A61N5/06 ,  A61P39/00

摘要： Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-001 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-001 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing α-rays, β-rays, γ-rays, neutron radiation, or a combination thereof.

公开(公告)号：US20240293360A1

公开(公告)日：2024-09-05

申请号：US18568625

申请日：2022-06-09

申请人： EpicentRx, Inc.

发明人： Bryan T. ORONSKY ,  Tony R. REID ,  Christpoher LARSON ,  James KANTER

IPC分类号： A61K31/397 ,  A61K9/14 ,  A61K35/14 ,  A61K47/10 ,  A61P35/00 ,  C07D205/04

CPC分类号： A61K31/397 ,  A61K9/145 ,  A61K35/14 ,  A61K47/10 ,  A61P35/00 ,  C07D205/04

摘要： The present invention relates to a composition comprising solid crystalline, non-impact or non-detonation sensitive particles comprising 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), methods of preparing the crystalline form, and its use.

公开(公告)号：US20240148692A1

公开(公告)日：2024-05-09

申请号：US18211792

申请日：2023-06-20

申请人： EpicentRx, Inc.

发明人： Bryan T. ORONSKY ,  Tony R. REID ,  Arnold ORONSKY

IPC分类号： A61K31/397

CPC分类号： A61K31/397 ,  A61K9/0014

摘要： Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OOI and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OOI to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing α-rays, β-rays, γ-rays, neutron radiation, or a combination thereof.

公开(公告)号：US11925617B2

公开(公告)日：2024-03-12

申请号：US17186724

申请日：2021-02-26

申请人： EpicentRx, Inc. ,  Northrop Grumman Systems Corporation

发明人： Mark D. Bednarski ,  Susan Knox ,  Louis Cannizzo ,  Kirstin Warner ,  Robert Wardle ,  Stephen Velarde ,  Shoucheng Ning

IPC分类号： A61K31/397 ,  A61K9/00 ,  A61N5/10 ,  A61P9/00 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  A61P43/00 ,  C07D205/02 ,  C07D205/04

CPC分类号： A61K31/397 ,  A61K9/0019 ,  A61N5/10 ,  C07D205/04

摘要： The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

公开(公告)号：US20240052016A1

公开(公告)日：2024-02-15

申请号：US18494508

申请日：2023-10-25

申请人： EpicentRX, Inc.

发明人： Christopher LARSON ,  Tony R. Reid ,  Bryn T. Oronsky

IPC分类号： C07K14/715 ,  A61P35/00 ,  C07K14/54 ,  C12N15/62

CPC分类号： C07K14/7155 ,  A61P35/00 ,  C07K14/5428 ,  C12N15/62 ,  A61K38/00

摘要： Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US11744859B2

公开(公告)日：2023-09-05

申请号：US16629099

申请日：2018-07-06

申请人： EpicentRx, Inc.

发明人： Bryan T. Oronsky

IPC分类号： A61K36/00 ,  A61K35/16 ,  A61P35/00 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/4745 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7042 ,  A61K35/15 ,  A61K47/46 ,  A61K9/00

CPC分类号： A61K35/16 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/4745 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7042 ,  A61K35/15 ,  A61K47/46 ,  A61P35/00 ,  A61K9/0019

摘要： The invention provides compositions and methods for administering a therapeutic agent to a patient, such as pharmaceutical compositions containing a blood product and a therapeutic agent selected from an anthracycline anti-cancer agent (e.g., doxorubicin), a topoisomerase inhibitor, an oxazaphosphinanyl anti-cancer agent, a nitro-aryl anti-cancer agent, a thiol-reactive functional group agent, a nitric oxide modulator, a platinum-based antineoplastic compound, acrylamide, acrylonitrile, bis(4-fluorobenzyl)trisulfide, a cardiac glycoside, an anti-mitotic agent (e.g., paclitaxel), a nucleoside analog, an EGFR inhibitor, or an anti-microbial agent.

公开(公告)号：US11253608B2

公开(公告)日：2022-02-22

申请号：US15991745

申请日：2018-05-29

申请人： EpicentRx, Inc.

发明人： Christopher Larson ,  Bryan Oronsky ,  Tony R. Reid

IPC分类号： C12N15/85 ,  A61K47/68 ,  A61P35/00 ,  A61K47/69 ,  C12N7/04 ,  A61K48/00 ,  C12N15/62 ,  C12N7/02 ,  C12N15/86

摘要： Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

公开(公告)号：US11008287B2

公开(公告)日：2021-05-18

申请号：US16341538

申请日：2017-10-13

申请人： EpicentRx, Inc.

发明人： Bryan T. Oronsky ,  Jan Scicinski

IPC分类号： C07D205/04

摘要： The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoimmune disease, infection, or cancer in a patient. Exemplary sulfoxyalkyl organonitro compounds described herein include ((2-(3,3-dinitroaze-tidin-1-yl)-2-oxoethyl)sulfinyl)-D-alanine and variants thereof.

公开(公告)号：US10906957B2

公开(公告)日：2021-02-02

申请号：US15717199

申请日：2017-09-27

申请人： EpicentRx, Inc.

发明人： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

IPC分类号： C07K14/71 ,  C12N7/00 ,  A61P35/00 ,  C07K16/00 ,  C12N15/86 ,  A61K48/00 ,  A61K35/768 ,  A61K38/00

摘要： Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20240294883A1

公开(公告)日：2024-09-05

申请号：US18649467

申请日：2024-04-29

申请人： EpicentRx, Inc.

发明人： Tony R. REID ,  Bryan T. ORONSKY ,  Christopher LARSON

IPC分类号： C12N7/00

CPC分类号： C12N7/00 ,  C12N2710/10321 ,  C12N2710/10322 ,  C12N2710/10332 ,  C12N2710/10352

摘要： The present disclosure relates to compositions and methods for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.